Drug Trial Radar · NCT04102241
Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis
Last checked: Nov 19, 2026Latest source record: Oct 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
216
Actual
Start
May 30, 2019
Primary completion
Oct 12, 2020
Study completion Jul 21, 2021
Sponsor
- Lead sponsor
- Tianjin Hemay Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 25, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hemay005 is a novel phosphodiesterase type 4(PDE4) inhibitor being developed for the treatment of psoriasis.After single asending dose and mutiple asending dose in health subjects. And the patients with moderate to severe plaque psoriasis will be randomized into 4 cohorts(15mg, 30mg, 60mg and placebo) approximately 216 subjects will be enrolled (52 for each cohort ). This study includes an 16-week treatment Period, then a 36-week Treatment Period without placebo.
Conditions
- Psoriasis
Interventions
15mg Hemay005Drug
Hemay005 is a small molecule PDE4 inhibitor.
PlacebosDrug
Placebos are the same as drugs, but contain no Hemay005.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects who have 75% or more reduction in [Psoriasis area-and-severity index score (PASI)] (PASI75).Time frame: week16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.